ARIH2

ARIH2 Full Name

ariadne homolog 2 (Drosophila)

ARIH2 Introduction

Ariadne RBR E3 Ubiquitin Protein Ligase 2 (ARIH2), also widely known as TRIAD1, is a highly conserved RBR-type E3 ubiquitin ligase belonging to the Ariadne family, serving as a core post-translational regulatory enzyme that governs cellular proteostasis, immune homeostasis, DNA damage response, and tumor cell fate in mammalian cells. Encoded by the ARIH2 gene located on human chromosome 3p21.31, this enzyme is ubiquitously expressed across human tissues, with prominent functional enrichment in immune cells, epithelial cells, and proliferative somatic tissues. As a canonical RBR (RING-Between-RING) E3 ligase, ARIH2 mediates substrate-specific polyubiquitination, targeting diverse downstream proteins for proteasomal degradation or functional modification to fine-tune multiple intracellular signaling cascades. It participates in a broad spectrum of fundamental biological processes, including protein quality control, inflammatory signal regulation, cell cycle modulation, and myeloid cell differentiation. Accumulating molecular and clinical studies demonstrate that ARIH2 acts as a critical molecular hub balancing cell proliferation, immune activation, and genomic stability. Dysregulated ARIH2 expression, functional defects, or mutational alterations are closely associated with neurodevelopmental disorders, chronic inflammatory diseases, and multiple human malignancies, making ARIH2 an essential ubiquitin regulatory gene and a valuable clinical prognostic biomarker.

Figure 1. Schematic structure of ARIH2.

Pathophysiological and Clinical Significance of ARIH2
Aberrant expression, catalytic dysfunction, or genetic mutation of ARIH2 profoundly drives the progression of neurodevelopmental disorders, chronic inflammatory diseases, and multiple human cancers, possessing critical clinical diagnostic and translational therapeutic value. In neuropsychiatric disorders, de novo ARIH2 mutations are closely linked to autism spectrum disorder and intellectual disability, characterized by impaired neural cell differentiation and abnormal brain developmental remodeling. In inflammatory pathology, ARIH2 deficiency disrupts innate immune signaling balance, leading to overactivated inflammatory cascades and persistent tissue inflammation. In human malignancies, ARIH2 exhibits context-dependent tumor regulatory functions. In gastric cancer and other solid tumors, elevated ARIH2 expression promotes cancer cell proliferation, enhances DNA damage tolerance, and reduces chemotherapy sensitivity by destabilizing p21 protein. Meanwhile, ARIH2 modulates p53 signaling activity in a tumor-specific manner, affecting tumor cell cycle arrest and apoptotic responses. Clinically, abnormal ARIH2 expression levels are tightly correlated with tumor pathological grade, malignant proliferation ability, and patient clinical prognosis, serving as a novel independent prognostic biomarker and a potential targeted therapeutic candidate for multiple human diseases.

Functions in Ubiquitination and Immune Signaling
ARIH2 plays critical roles in the regulation of innate immunity, inflammation, and cell proliferation through its E3 ubiquitin ligase activity. ARIH2 is a key component of the linear ubiquitin chain assembly complex (LUBAC), which consists of the catalytic subunit HOIP, the adaptor SHARPIN, and the regulatory subunit HOIL-1L. ARIH2 functions as a priming E3 ligase that generates the initial ubiquitin chains on substrates, which are then extended by HOIP to form linear (M1-linked) polyubiquitin chains. Linear ubiquitin chains are critical for the activation of the NF-κB pathway downstream of tumor necrosis factor receptor (TNFR), interleukin-1 receptor (IL-1R), and Toll-like receptors (TLRs). By facilitating linear ubiquitination of NEMO (IKKγ) and RIPK1, ARIH2 promotes the assembly of the IKK complex and subsequent NF-κB activation, leading to the expression of pro-inflammatory cytokines and cell survival genes. In addition to its role in LUBAC, ARIH2 functions as a negative regulator of inflammatory signaling by ubiquitinating and degrading key signaling intermediates. ARIH2 directly ubiquitinates and promotes the degradation of TRAF3 (TNF receptor-associated factor 3), which is a critical adaptor in TLR and RIG-I-like receptor (RLR) signaling pathways. By degrading TRAF3, ARIH2 limits the production of type I interferons (IFN-α and IFN-β) in response to viral infection, preventing excessive inflammation.

Alternate Names for ARIH2

ARIH2; ariadne homolog 2 (Drosophila); ariadne (Drosophila) homolog 2; E3 ubiquitin-protein ligase ARIH2; all trans retinoic acid inducible RING finger; TRIAD1; ARI-2; protein ariadne-2 homolog; all-trans retinoic acid inducible RING finger; ARI2; FLJ10938; FLJ33921;